Can Preimplantation Genetic Testing Be Used for Sex Selection?
Key Takeaways
PGT can reveal embryo sex because the test examines chromosomal or genetic information, but that does not mean sex selection is always appropriate or allowed. Medical use to avoid serious sex-linked disease is treated differently from non-medical selection, which remains ethically controversial and legally restricted in many jurisdictions.
Can Preimplantation Genetic Testing Be Used for Sex Selection?
Preimplantation genetic testing (PGT) is performed within an IVF cycle to analyze embryos before transfer. Because PGT examines chromosomes or specific gene changes, it can also reveal the sex chromosomes of the embryo. This means embryo sex may become known during the testing process, but whether it can be used for selection depends on why the testing is being done and where treatment is taking place.
Why PGT Can Reveal Embryo Sex
PGT includes several different applications:
- PGT-A evaluates chromosome number.
- PGT-M looks for a specific inherited single-gene disorder.
- PGT-SR assesses structural chromosome rearrangements.
Because sex chromosomes are part of the embryo’s genetic profile, embryo sex may be identified during testing even when sex selection is not the primary purpose.
When Sex Selection May Be Used for Medical Reasons
The clearest medical indication is the prevention of a serious sex-linked disorder. Some inherited conditions mainly affect one sex, especially certain X-linked disorders. In those situations, clinicians may use PGT as part of a broader plan to reduce the risk of transferring an affected embryo.
This is different from selecting embryo sex for preference alone. In medical use, the goal is disease avoidance rather than family balancing or personal choice.
Why Non-Medical Sex Selection Is Controversial
Non-medical sex selection raises ethical concerns about gender bias, reproductive fairness, and the broader expansion of embryo selection beyond disease prevention. Professional bodies have also noted the practical issue that embryo selection should prioritize clinical quality and patient goals rather than reduce decision-making to one non-medical trait.
Another important point is that PGT is not a harmless add-on performed in isolation. It requires IVF, embryo biopsy, and laboratory testing, all of which carry cost, complexity, and some uncertainty.
Legal and Policy Differences Matter
Rules differ widely by country and by clinic policy. Some settings allow broader patient choice, while others restrict sex selection to medical indications. Even where embryo sex is incidentally visible on a report, clinics may have specific policies on whether and when that information is disclosed.
Because regulations change and vary by jurisdiction, patients should not assume that a practice allowed in one country or clinic is accepted elsewhere.
Clinical Perspective
The main medical aim of PGT is to support embryo selection for genetic or chromosomal reasons, not to promise a child of a chosen sex. Even when sex information is available, embryo viability, genetic findings, and the overall IVF context remain more important for treatment planning.
Conclusion
Yes, PGT can reveal embryo sex, and in some medical situations it may be part of a justified decision to avoid serious sex-linked disease. But non-medical sex selection remains ethically disputed and often legally limited, so the answer depends on both the indication and the regulatory setting.
Related Reading
- PGT-M for Monogenic Diseases: How It Works and What It Can and Cannot Do
- Embryo Grades Like 4AA, 3BB, and 5BC: What They Actually Mean
- IVF Risks and Practical Considerations: What Patients Should Know
FAQ
Does every PGT report show embryo sex?
Not necessarily. Some testing methods can identify sex chromosomes, but disclosure depends on the test type, the clinic’s policy, and the law in the treatment location.
Is sex selection for family balancing the same as medical sex selection?
No. Medical use is usually discussed when embryo sex is linked to a serious inherited condition. Family balancing is a non-medical request and is treated differently by many professional and legal systems.
Does choosing embryo sex improve IVF success?
No. Embryo sex is not a marker of implantation potential. Embryo development, chromosomal findings, uterine factors, and patient-specific context are more relevant to treatment planning.
Should patients travel for non-medical sex selection?
Patients should be cautious. Laws, consent rules, reporting requirements, and ethical guidance differ by country, and a practice offered elsewhere may not be appropriate or available in their own clinical setting.
Sources
- American Society for Reproductive Medicine. Use of reproductive technology for sex selection for nonmedical reasons: an Ethics Committee opinion (2022).
- American Society for Reproductive Medicine. The use of preimplantation genetic testing for aneuploidy: a committee opinion (2024).
- American College of Obstetricians and Gynecologists. Preimplantation genetic testing.
The content has been created by Dr. Senai Aksoy and medically approved.